Table A5.
PRO Scores by OFS Type in Patients in the Tamoxifen + OFS Arm
| PRO/Time Point | LHRH Agonist |
Oophorectomy |
Radiation |
P (ANOVA test) | |||
|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Mean | SD | ||
| FACT-B | |||||||
| Baseline | 109.30 | 20.95 | 112.90 | 17.74 | 108.20 | 15.15 | .60 |
| Month 6 | 113.10 | 18.94 | 111.50 | 18.28 | 113.90 | 17.02 | .85 |
| Year 1 | 111.70 | 20.16 | 110.90 | 18.43 | 112.20 | 15.89 | .95 |
| Year 2 | 107.10 | 20.41 | 112.30 | 17.85 | 111.80 | 13.83 | .38 |
| Year 3 | 116.60 | 18.83 | 107.60 | 16.14 | 116.60 | 18.67 | .040 |
| Year 4 | 115.10 | 22.15 | 111.30 | 17.80 | 114.60 | 19.29 | .68 |
| Year 5 | 117.50 | 15.15 | 116.00 | 14.35 | 116.50 | 18.34 | .92 |
| FACT-G | |||||||
| Baseline | 86.65 | 14.82 | 86.61 | 12.63 | 83.23 | 11.93 | .55 |
| Month 6 | 87.10 | 14.15 | 85.89 | 14.35 | 86.15 | 16.96 | .91 |
| Year 1 | 86.60 | 16.12 | 86.31 | 14.05 | 87.06 | 13.09 | .98 |
| Year 2 | 83.87 | 15.09 | 87.44 | 14.22 | 88.13 | 11.61 | .39 |
| Year 3 | 91.05 | 14.71 | 84.82 | 13.03 | 89.13 | 15.19 | .10 |
| Year 4 | 89.39 | 16.35 | 87.62 | 14.22 | 89.31 | 15.21 | .84 |
| Year 5 | 91.90 | 12.37 | 88.58 | 12.15 | 90.43 | 14.55 | .54 |
| Breast subscale | |||||||
| Baseline | 25.89 | 5.81 | 25.20 | 5.43 | 24.44 | 6.13 | .71 |
| Month 6 | 25.94 | 6.11 | 25.30 | 5.44 | 25.22 | 3.89 | .81 |
| Year 1 | 24.91 | 5.31 | 24.55 | 6.01 | 25.17 | 5.61 | .90 |
| Year 2 | 23.24 | 6.16 | 24.43 | 5.97 | 23.46 | 4.29 | .60 |
| Year 3 | 25.45 | 5.21 | 23.49 | 5.79 | 27.36 | 4.18 | .040 |
| Year 4 | 25.56 | 6.57 | 24.29 | 5.48 | 25.33 | 5.10 | .60 |
| Year 5 | 25.90 | 5.27 | 26.09 | 5.65 | 25.54 | 5.90 | .95 |
| PEPI | |||||||
| Baseline | 48.28 | 7.74 | 49.28 | 8.03 | 49.66 | 7.35 | .70 |
| Month 6 | 42.37 | 8.40 | 38.97 | 8.17 | 38.48 | 9.65 | .09 |
| Year 1 | 41.17 | 7.75 | 37.86 | 8.90 | 40.41 | 7.48 | .10 |
| Year 2 | 39.50 | 8.95 | 38.34 | 6.51 | 36.57 | 6.84 | .44 |
| Year 3 | 42.25 | 7.04 | 38.25 | 8.53 | 39.88 | 9.02 | .07 |
| Year 4 | 41.43 | 8.40 | 40.05 | 7.88 | 40.29 | 7.43 | .74 |
| Year 5 | 42.08 | 8.22 | 41.17 | 7.76 | 42.92 | 6.05 | .74 |
| SAQ | |||||||
| Baseline | 16.49 | 3.23 | 15.90 | 3.74 | 15.74 | 4.25 | .61 |
| Month 6 | 14.42 | 4.35 | 12.19 | 3.88 | 13.53 | 4.68 | .041 |
| Year 1 | 14.12 | 3.87 | 11.45 | 4.78 | 13.27 | 4.91 | .012 |
| Year 2 | 13.13 | 5.07 | 11.16 | 4.33 | 10.90 | 2.82 | .09 |
| Year 3 | 13.11 | 3.95 | 10.14 | 4.82 | 10.85 | 5.24 | .014 |
| Year 4 | 12.27 | 4.18 | 10.85 | 5.04 | 10.69 | 4.44 | .43 |
| Year 5 | 12.56 | 3.97 | 10.68 | 4.88 | 11.11 | 3.33 | .25 |
Abbreviation: ANOVA, analysis of variance; FACT-B, Functional Assessment of Cancer Therapy-Breast; FACT-G, FACT-General; LHRH, luteinizing hormone-releasing hormone; OFS, ovarian function suppression; PEPI, Postmenopausal Estrogen/Progestin Intervention (checklist); PRO, patient-reported outcome; SAQ, Sexual Activity Questionnaire; SD, standard deviation.